文献速递心脑血管急症

急性缺血性卒中取栓前静脉溶栓的时间与功能结局:一项荟萃分析

Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic Stroke: A Meta-Analysis.
PubMed 文献 · JAMA · 2024-01-01
一句话结论在具备取栓能力的卒中中心,取栓前静脉溶栓的获益随时间延长而下降,仅在症状发作至预期溶栓时间较短时(约2小时20分钟内)才有统计学意义。

该个体参与者数据荟萃分析纳入6项随机临床试验,比较静脉溶栓(IVT)联合取栓与单纯取栓,共2313例前循环大血管闭塞且适合IVT和取栓的患者。主要分析显示,症状发作至预期IVT给药时间与治疗分配和90天功能结局的关联存在显著交互作用(每延迟1小时的调整共同OR比值为0.84,95%CI 0.72-0.97,交互P=0.02)。IVT联合取栓的获益随时间延长而下降:1小时调整共同OR 1.49(95%CI 1.13-1.96),2小时1.25(95%CI 1.04-1.49),3小时1.04(95%CI 0.88-1.23);mRS 0-2的预测绝对风险差在1小时为9%(95%CI 3%-16%),2小时为5%(95%CI 1%-9%),3小时为1%(95%CI -3%-5%)。超过2小时20分钟后,IVT联合取栓的获益不再有统计学意义,点估计在3小时14分钟时跨越无效线。

要点

  • 在适合IVT和取栓的前循环大血管闭塞患者中,IVT联合取栓的获益与症状发作至预期IVT给药时间显著交互(每延迟1小时调整共同OR比值0.84,95%CI 0.72-0.97,交互P=0.02)。
  • IVT联合取栓的调整共同OR(mRS改善1步)在1小时为1.49(95%CI 1.13-1.96),2小时为1.25(95%CI 1.04-1.49),3小时为1.04(95%CI 0.88-1.23)。
  • mRS 0-2的预测绝对风险差在1小时为9%(95%CI 3%-16%),2小时为5%(95%CI 1%-9%),3小时为1%(95%CI -3%-5%)。
  • 超过2小时20分钟后,IVT联合取栓的获益不再有统计学意义,点估计在3小时14分钟时跨越无效线。
  • 患者均在具备取栓能力的卒中中心直接就诊,中位症状发作至预期IVT给药时间为2小时28分钟(IQR 1小时46分钟-3小时17分钟)。

适用人群与场景

  • 纳入:6项随机临床试验中适合IVT和取栓、直接就诊于具备取栓能力的卒中中心的前循环大血管闭塞患者(n=2313)。
  • 排除:非前循环大血管闭塞患者(从2334例中排除后纳入2313例)。

研究设计与关键结果

  • 研究类型:个体参与者数据荟萃分析,纳入6项随机临床试验,比较IVT联合取栓与单纯取栓。
  • 样本量与场景:2017年1月至2021年7月在15个国家190个中心入组,共2334例,本分析纳入前循环大血管闭塞2313例(IVT联合取栓组1160例 vs 单纯取栓组1153例;中位年龄71岁[IQR 62-78],女性44.3%)。
  • 主要终点:症状发作至预期IVT给药时间与治疗分配和90天功能结局(7级mRS)的关联存在显著交互作用(每延迟1小时的调整共同OR比值0.84,95%CI 0.72-0.97,交互P=0.02)。
  • IVT联合取栓的获益随时间延长而下降:调整共同OR(mRS改善1步)在1小时为1.49(95%CI 1.13-1.96),2小时为1.25(95%CI 1.04-1.49),3小时为1.04(95%CI 0.88-1.23)。
  • mRS 0-2的预测绝对风险差:1小时为9%(95%CI 3%-16%),2小时为5%(95%CI 1%-9%),3小时为1%(95%CI -3%-5%)。
  • 超过2小时20分钟后,IVT联合取栓的获益不再有统计学意义,点估计在3小时14分钟时跨越无效线。

证据类型、等级与局限

  • 证据类型:个体参与者数据荟萃分析(6项随机临床试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在具备取栓能力的卒中中心就诊的患者中,IVT联合取栓与单纯取栓相比的获益具有时间依赖性,仅在症状发作至预期IVT给药时间较短时有统计学意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The benefit of intravenous thrombolysis (IVT) for acute ischemic stroke declines with longer time from symptom onset, but it is not known whether a similar time dependency exists for IVT followed by thrombectomy.

OBJECTIVE: To determine whether the benefit associated with IVT plus thrombectomy vs thrombectomy alone decreases with treatment time from symptom onset.

DESIGN, SETTING, AND PARTICIPANTS: Individual participant data meta-analysis from 6 randomized clinical trials comparing IVT plus thrombectomy vs thrombectomy alone. Enrollment was between January 2017 and July 2021 at 190 sites in 15 countries. All participants were eligible for IVT and thrombectomy and presented directly at thrombectomy-capable stroke centers (n = 2334). For this meta-analysis, only patients with an anterior circulation large-vessel occlusion were included (n = 2313).

EXPOSURE: Interval from stroke symptom onset to expected administration of IVT and treatment with IVT plus thrombectomy vs thrombectomy alone.

MAIN OUTCOMES AND MEASURES: The primary outcome analysis tested whether the association between the allocated treatment (IVT plus thrombectomy vs thrombectomy alone) and disability at 90 days (7-level modified Rankin Scale [mRS] score range, 0 [no symptoms] to 6 [death]; minimal clinically important difference for the rates of mRS scores of 0-2: 1.3%) varied with times from symptom onset to expected administration of IVT.

RESULTS: In 2313 participants (1160 in IVT plus thrombectomy group vs 1153 in thrombectomy alone group; median age, 71 [IQR, 62 to 78] years; 44.3% were female), the median time from symptom onset to expected administration of IVT was 2 hours 28 minutes (IQR, 1 hour 46 minutes to 3 hours 17 minutes). There was a statistically significant interaction between the time from symptom onset to expected administration of IVT and the association of allocated treatment with functional outcomes (ratio of adjusted common odds ratio [OR] per 1-hour delay, 0.84 [95% CI, 0.72 to 0.97], P = .02 for interaction). The benefit of IVT plus thrombectomy decreased with longer times from symptom onset to expected administration of IVT (adjusted common OR for a 1-step mRS score shift toward improvement, 1.49 [95% CI, 1.13 to 1.96] at 1 hour, 1.25 [95% CI, 1.04 to 1.49] at 2 hours, and 1.04 [95% CI, 0.88 to 1.23] at 3 hours). For a mRS score of 0, 1, or 2, the predicted absolute risk difference was 9% (95% CI, 3% to 16%) at 1 hour, 5% (95% CI, 1% to 9%) at 2 hours, and 1% (95% CI, -3% to 5%) at 3 hours. After 2 hours 20 minutes, the benefit associated with IVT plus thrombectomy was not statistically significant and the point estimate crossed the null association at 3 hours 14 minutes.

CONCLUSIONS AND RELEVANCE: In patients presenting at thrombectomy-capable stroke centers, the benefit associated with IVT plus thrombectomy vs thrombectomy alone was time dependent and statistically significant only if the time from symptom onset to expected administration of IVT was short.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kaesmacher J, Cavalcante F, Kappelhof M, et al. Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic Stroke: A Meta-Analysis. JAMA. 2024. PMID: 38324409. doi:10.1001/jama.2024.0589

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。